Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 9/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | RET | P07949 | 6/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | CSF1R | P07333 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923109 | 0.96 | HRH3 (0.65) | PRKD1HRH3RETKDRCSF1R | |
| SCHEMBL962069 | 0.93 | PRKD1 (0.66) | PRKD1RETKDRFLT3AURKA | |
| SCHEMBL1079502 | 0.85 | PRKD1 (0.70) | PRKD1 | |
| SCHEMBL959960 | 0.81 | PRKD1 (0.58) | PRKD1 | |
| SCHEMBL936788 | 0.81 | PRKD1 (0.65) | PRKD1HRH3RETKDR | |
| SCHEMBL1053391 | 0.81 | PRKD1 (0.70) | PRKD1 | |
| SCHEMBL960488 | 0.81 | PRKD1 (0.70) | PRKD1 | |
| SCHEMBL6924065 | 0.81 | PRKD1 (0.64) | PRKD1HRH3RETKDR | |
| SCHEMBL6924052 | 0.81 | PRKD1 (0.69) | PRKD1 | |
| SCHEMBL1056077 | 0.79 | PRKD1 (0.76) | PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011009484-A1 | ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009484-A1 | ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |